Patent Application
20180078659
Theranostic therapies—treatments that can diagnose and deliver targeted therapy—are invaluable instruments in the fight against diseases, such as cancer and atherosclerosis. Nanoparticles can be loaded with drugs and contrast agents, targeted to affect specific proteins, and monitored via molecular imaging for cellular uptake and drug release. This targeted technique has less detrimental side effects than general treatments due to the preservation of healthy cells.
Molecular imaging requires development of specific contrast-enhancing agents that can provide information about the distribution and activity of the cells and biomolecules involved at various stages of disease progression. The field of nanomaterials has introduced a variety of promising contrast-enhancing nanoparticles across different disciplines and imaging modalities. These new nanomaterials offer increased signal intensity, improved imaging contrast and superior binding affinity in comparison to “traditional” contrast agents (e.g. molecular-based contrast agents and monomeric dyes). Likewise, nanotechnology offers unique benefits due to its ability to interact with biological processes at the cellular and molecular level.
Liposomal nanoparticles are of interest due to their biocompatible, nontoxic nature and their potential be loaded with a variety of drugs, including doxorubicin and paclitaxel along with various contrast agents, such as dyes and plasmonic nanoparticles. Antibodies targeting molecular markers of diseased cells can be conjugated to the surface of the liposomes to initiate receptor mediated endocytosis by diseased cells; this uptake can result in the release of the liposomal payload. In turn, the uptake of liposomes can result in release of the dyes encapsulated within the lipid shell or core (for example through the same mechanisms that have been actively explored for liposomal drug delivery inside cells) that will lead to profound changes in dye optical properties. These changes can be monitored by a variety of optical imaging techniques ranging from traditional optical microscopy to near infrared spectroscopy, multispectral imaging, photoacoustic imaging and fluorescence.
In general, unlike “traditional” contrast agents, polymethine dye-aggregate loaded liposomes may have the ability to interact with and sense cellular induced behavior (like endocytosis via receptor-mediated binding) via their changing optical absorption spectra and/or fluorescence. Furthermore, if polymethine dye-aggregate loaded liposomes, or liposomes loaded specifically with indocyanine green (ICG) J-aggregates, are also loaded with drugs, then the same change in optical properties of the dye that can be monitored to sense cellular behavior, can also confirm drug delivery at a cellular level, making polymethine dye-aggregate loaded liposomes a unique and ideal choice for molecular and cellular specific, sensitive imaging.
The present disclosure generally relates to cellular sensing and drug delivery. More specifically, the present disclosure relates to methods of detecting cellular function and/or targeted drug delivery in biological tissues, biological organisms in general and biological systems using dye-loaded liposomes.
An embodiment of the present invention provides a method for sensing dissociation of dye-aggregates due to the rupture of particles consisting of the dye in liposomes, based on changes in their absorption spectra. According to this embodiment, the method includes a step of monitoring the first and/or second peak absorbance ranges of about 870-920 nm (aggregate peak) and about 760-810 nm (monomer peak). An increase or decrease of either peak by more than at least 2 percent of the baseline values may be used to detect the extent of dissociation activity. In other embodiments, such extent may be determined by performing ratiometric analysis of the characteristic aggregate and monomer peaks to determine degree of liposomal rupture. The liposomal particle may comprise a liposome, a coating on the surface of the liposome, with or without a targeting moiety within the coating and a plurality of dye-aggregates within the liposome. Upon rupture of the liposome, the aggregates may be dissolved by the surrounding media or intracellular components, inducing a decrease in the aggregate peak with respect to that of the monomer.
Further methods of detecting the extent of dissociation activity include a step of monitoring absorbance spectra and detecting of reduction in absorbance peak in the first wavelength range (aggregate peak), such absorbance being at or below a first predefined threshold, such as for example about 2 percent, 3 percent, 4 percent, 5 percent, 6 percent, 7 percent, 8 percent, 9 percent, or 10 percent reduction or greater of the baseline level of the absorbance spectra.
In other embodiments, the extent of dissociation activity may be further detected by monitoring the increase in the second wavelength range corresponding to the monomer peak of the dye. In this case, dissociation of aggregates may be established after detecting an increase in absorbance peak in the second wavelength range at or above a second predefined threshold, such as for example about 2 percent, 3 percent, 4 percent, 5 percent, 6 percent, 7 percent, 8 percent, 9 percent, 10 percent increase or more over the baseline level of the absorbance spectra.
Another embodiment provides a method for sensing dissociation of dye-aggregates due to the rupture of particles consisting of dye in aggregate form encapsulated in liposomes, based on changes in their fluorescence, which can be monitored using near infrared fluorescence among other techniques. According to this embodiment, the method comprises a step of monitoring the fluorescence of the dye-loaded liposomal constructs to detect an increase or decrease in signal upon rupture. The liposomal particle may comprise a liposome, a coating on the surface of the liposome, with or without a targeting moiety within the coating, and a plurality of dye-aggregates within the liposome. Upon rupture of the liposome, the aggregates may be dissolved by the surrounding media or intracellular components, inducing an increase in fluorescence due to a reduction in self-quenching.
Yet another embodiment provides methods of detection of cellular uptake, with or without targeted delivery or a therapeutic or diagnostic agent. According to this embodiment, the method comprises a step of introducing targeted liposomes to a biological tissue or system to detect cellular uptake based on the dissociation of dye-aggregates after uptake and liposomal rupture. The targeted liposomal particle may in that case comprise a liposome, a coating on the surface of the liposome, a targeting moiety within the coating, a plurality of dye-aggregates within the liposome, and with or without a payload, such as a drug that is housed within or tethered to the lipids in the liposome itself. Upon cellular uptake of the particle, the liposome may rupture and the aggregates may be dissolved. The absorption spectra and/or fluorescence may be monitored via imaging techniques, such as photoacoustic imaging or fluorescence imaging or a variety of other optical imaging techniques, to detect the changes highlighted in the previously mentioned embodiments and confirm targeted uptake and payload delivery.
Some specific example embodiments of the disclosure may be understood by referring, in part, to the following description and the accompanying drawings.
The present disclosure provides, according to certain embodiments, methods for sensing the dissociation of dye aggregates due to the rupture of particles consisting of said dye in liposomes. Such particles may be used as contrast agents and sensors to monitor cellular activity or drug delivery for various imaging techniques. Although the sensing methods are described below utilizing ICG J-aggregate loaded liposomes, the methods of the present disclosure may utilize other aggregate forming dyes of the polymethine class.
In accordance with embodiments of the present invention, provided is a dye-aggregate loaded liposome. Additionally, embodiments of the present invention provide methods of sensing by monitoring the absorption and/or fluorescence spectra of these particles via a variety of imaging techniques. Such imaging techniques may include ultrasound imaging, photoacoustic imaging, fluorescence imaging, near infrared fluorescence imaging, near infrared spectroscopy imaging, two-photon luminescence, optical coherence tomography imaging, and optical frequency domain imaging. In embodiments, such imaging may be conducted in vivo (for example using an intravascular catheter-based imaging probe, laparoscopic device, or a transcutaneous imaging probe) or using an ex-vivo assay. Such imaging may also be conducted during surgery for a purpose of spatial guidance, for a diagnostic purpose, or for a purpose of monitoring of disease recurrence. The imaging may be done using either a laparoscopic device, an endoscope, or a surface imaging probe.
One of the many advantages of the present invention is that the size of the liposome may be selected to allow for passive diffusion into tumor tissues, and therefore, may be easily used for therapy and imaging for many pathologies. The small size of the particle may allow the liposome to travel almost anywhere in the body where therapy and/or imaging may be required. For example, embodiments incorporating therapeutic agents could act as drug delivery and drug release systems for active cellular uptake sensing.
Another advantage of the current invention is the robustness of the sensing method. The liposomal constructs are highly stable due to the inclusion of aggregates. The large aggregates prevent dye leakage allowing for consistent delivery of the full payload to cells. The current invention relies upon the disruption of liposomes within cells or disruption due to cellular activity. The aggregates may then be dissolved due to a decrease in local concentration upon rupture.
An additional advantage of the current invention is utilizing a construct that is completely biocompatible and easily cleared after detection. By utilizing indocyanine green (ICG) dye and lipids, all components of the construct have been approved by the Food and Drug Administration for use within the human body for other applications. Numerous other dyes within the polymethine class are currently undergoing clinical trials with encouraging results. Upon rupture, the lipid shell is dispersed, likely incorporating into cell walls or getting repackaged by the cell, and the dye is cleared soon after by the renal system, giving a distinct advantage over other contrast agents that may accumulate in the liver and spleen. The last dissolution of dye upon rupture provides instant feedback on the extent of the cellular uptake and interaction.
Further advantages of the current invention include applicability to various cellular systems. The liposomes may be functionalized with antibodies, antibody fragments, folates, aptamers, vitamins, and/or polymers, allowing targeting of a wide range of cell types. As the sensing mechanism depends upon breakdown of the liposome and associated aggregates upon cellular uptake, this creates a possibility for targeting cells outside of biological tissue; particularly, harmful biological agents. Bacterial targeting could be employed coupled with the sensing mechanism to provide a rapid spectral detection method for released biological agents, acting as a warning system in bioterrorism or biological warfare.
Atherosclerosis and cancer are two examples of advantageous use of the therapeutic or diagnostic methods of the present invention. In atherosclerosis for example, antibodies of the invention may be used to target macrophages, foam cells, or other inflammatory cells in plaques, as well as other white blood cells, smooth muscle cells, or endothelial cells. Antibody targets may further include folate receptor beta, markers of apoptosis (annexins), markers of glucose uptake, proteinases (such as MMPs), multiple clusters of differentiation including CD36, and CD68. Other molecular targets of interest may include P-selectin, VCAM-1, ICAM-1, VLA-4, JAM-A, Connexin 43, CCL2(MCP-1)/CCR2, CCL5(RANTES)/CCR5, CX3CL1(fractal-kine)CX3CR1, and MIF. Further target applications in atherosclerosis may be found in the article by Meyer I D, Martinet W, and Meyer G entitled “Therapeutic strategies to deplete macrophages in atherosclerotic plaques”, British Journal of Clinical Pharmacology, 74;2:246-263, 2012, incorporated herein in its entirety by reference.
Various types of therapeutic agents may be used for the methods of the present invention. Examples of such agents include clodronate, lithium chloride, recombinant TRAIL, NO donor, thapsigargin and tunicamycin, cycloheximide and anisomycin, mTOR inhibitor (everolimus), imiquimod, glucocorticoids, CpG oligonucleotides, clot-dissolving drugs, and RNA in general.
In the field of oncology, the present invention may find uses with antibodies used to target cancer cells or inflammatory cells. A long list of suitable antibody targets may be considered to include those on cancer cells and inflammatory cells. Examples may include folate receptor beta, markers of apoptosis (annexins), markers of glucose uptake, proteinases (such as MMPs), multiple clusters of differentiation including CD36 and CD68, P-selectin, VCAM-1, ICAM-1, VLA-4, JAM-A, Connexin 43, CCL2(MCP-1)/CCR2, CCL5(RANTES)/CCR5, CX3CL1(fractal-kine)CX3CR1, MIF, EGFR, TGF beta, folate receptors in general. PSMA, HER2, VEGF, interleukin 4, interleukin 10, and interleukin 13.
Examples of suitable therapeutic agents for cancer treatments may include chemotherapeutic drugs in general such as paclitaxel, doxorubicin, cisplatin, CpG oligonucleotides, and RNA in general. Immunotherapies can also be delivered such as trastuzamab, lapatinib, etc. A more exhaustive list of suitable therapeutic agents is described by Dougan, M. & Dranoff, G. in “Innate Immune Regulation and Cancer Immunotherapy” (ed. Rongfu Wang) p. 391-414 (Springer N.Y., 2012), which is incorporated herein by reference in its entirety.
Sensing techniques of the current invention differ from prior technologies in a number of aspects. First, the method relies on a change in conformation of an aggregate forming dye. This conformational change is forced upon disruption of the liposomal particle, creating a consistent shift in absorption spectra and fluorescence. Second, the method utilizes a particle effective for either or all of imaging, sensing cellular function, and drug delivery. Current known technologies allow targeted delivery and imaging, but the present invention may also include built-in sensing to monitor cellular uptake.
A sketch of one embodiment of the invention is illustrated in
A suitable therapeutic agent may be incorporated into a liposome in a number of ways, for example it may be contained within the core of the liposome, in the lipid bilayer, tethered to the lipid, or adhered either through covalent or electrostatic binding to the coating or lipid.
The liposome 100 may further comprise a coating 110, which may for example comprise bovine serum albumin (BSA), Polyethylene glycol (PEG), carbohydrates, or dextran, or combinations thereof. The coating 110 may further comprise one or more targeting mechanisms 150, such as antibodies, antibody fragments, folates, aptamers, vitamins, and/or polymers.
The sensing method of the invention may comprise detection of absorbance, which may utilize one or more imaging techniques mentioned above, such as photoacoustic imaging or UV-Vis-NIR (ultraviolet to visible to near infrared) spectroscopy. The sensing method may also comprise detection of fluorescence, which may utilize a suitable imaging technique, such as two-photon fluorescence, near infrared imaging, or fluorescence microscopy. The sensing method may further comprise visual detection, which may utilize an optical instrument such as optical microscopy or optical coherence tomography.
For the purposes of this description, a peak in absorbance spectra may be defined as a local maximum of absorbance intensity in the absorption spectra, which may be identified by a value of zero in the first or second derivative of the spectra. This may incorporate one or both local maxima and changes in concavity of the absorption spectra. Signal of interest may be at least 15% greater than noise in order to assure accurate observation and identification of the peak. In embodiments, an increase or a decrease of the baseline level by at least 2 percent may be considered as defining a local peak or valley. In other embodiments, a threshold to define a peak may be established as 5 percent of the baseline level change and in further embodiments that threshold may be established at 5 to 10 percent or more of the baseline level.
As noted above, the biocompatible dye may be any dye that forms aggregates resulting in a shift in their absorption spectra or fluorescence. Examples of suitable dyes that form these aggregates may include polymethines, including cyanines such as ICG, squaraines, and perylene bismides. Various polymethine dyes may be useful for the purposes of the present invention. Exemplary classes of polymethine dyes that are known to form either or both J and H aggregates at various concentrations are cyanines, merocyanines, squaraines, and rylenes. As concentration of the dye in solution increases, the dyes progress through H-aggregate polymeric formation yielding a hypsochromic (blue) shift in absorption spectra with a broad absorption peak. The H-aggregates may be composed of plane-to-plane organization of the dyes at a molecular level. When dye concentration is further increased, molecules organize head-to-tail, therefore forming J-aggregates. This supramolecular organization induces a bathochromic (red) shift in absorption with a sharp absorption peak.
Examples of cyanine dyes useful for the purposes of the invention may include an indocyanine green, Cy3, Cy3.5, Cy5.5, and Cy7. Useful examples of merocyanine dyes may include a pseudoisocyanine chloride and merocyanine I. Useful examples of squaraine dyes may include a squarylium dye III. Useful example of rylene dyes may include a perylene bismide.
The terms “coat,” “coated,” or “coating,” as used herein, also refer to at least a partial coating of a particle. One hundred percent coverage of a particle is not implied by these terms. Rather, a droplet may be coated if it has at least a partial coating.
To facilitate a better understanding of the present invention, the following examples of certain aspects of some embodiments are given. In no way should the following examples be read to limit, or define, the scope of the invention.
Liposomes of the invention may be synthesized via methods similar to those presented previously in literature. Specifically, the example outlined here utilized indocyanine green (ICG) J-aggregates loaded in liposomes to form 100 nm particles. Samples were purified to remove free ICG before further studies. Particles were stable after synthesis and stored in PBS, and monitored via ultraviolet-to visible-to near infrared (UV-Vis-NIR) light absorption spectrophotometry and fluorometry; these two techniques will be discussed here.
UV-Vis-NIR spectrophotometry was performed on a spectrophotometer with a 5 nm slit width, scanned over the wavelengths of 400-1100 nm, sampled every 1 nm, at 3 nm per second. Samples were prepared by diluting the ICG-loaded liposomes with water to a 0.1 mg/mL lipid concentration and loading 2.5 mL in a plastic cuvette. To disrupt the liposomes, a common nonionic liquid surfactant, Triton X-100, was used. A 10 vol % solution of Triton X-100 in water was prepared and added to the liposome solution in a 1:1 ratio. The UV-Vis-NIR spectra were collected before, during, and after disruption. As seen in
The fluorescence spectra was also collected for the constructs. The fluorescent intensity was calibrated with respect to the 397 nm (3380 cm−1) Raman peak of water. Samples were prepared with a constant ICG concentration of 0.025 mg/mL. ICG-loaded liposomes with water to a 0.125 mg/mL lipid concentration, yielding a 0.025 mg/mL total ICG concentration. To disrupt the liposomes, a common nonionic liquid surfactant, Triton X-100, was used. A 10 vol % solution of Triton X-100 in water was prepared and added to the liposome solution in a 1:10 ratio, 10 min before measurement. The fluorescent spectra were collected for free ICG and before and after disruption of the ICG J-aggregate loaded liposomes. As seen in
This example further illustrates an opportunity for a general, non-biologic use of the methods of the invention to detect a surfactant (like Triton X) in a liquid in the presence of liposomes with encapsulated J-aggregates of ICG.
ICG J-aggregate loaded liposomes were tested for their applicability as cellular uptake sensors. About 50,000 J774 A.1 macrophages (ATCC) were seeded onto coverslips in a 6-well plate. ICG J-aggregate loaded liposomes and free ICG J-aggregates were added to the cell media for 2 hours to allow uptake by cells. Following uptake, coverslips were washed with PBS to remove any free dye or liposome, and then imaged using a 75 W Xenon light source and Leica DM6000 upright microscope. Fluorescence images were acquired with a 600 nm excitation and a red low pass filter. Images were collected through a 20×0.5NA objective and detected using a SPOT 1.4MP color mosaic camera.
For spectral analysis, J774 A.1 cells were plated on 96 well plates at 105 cells per well. 100 μL of phenol free media was added to each well and the cells were incubated 24 hrs at 37° C. in 5% CO2. The media was aspirated, and either ICG J-aggregate loaded liposomes, fresh ICG, or free ICG J-aggregates were added to the cells in phenol free growth media. Cells were then incubated for 4 hrs. After incubation, the cells were rinsed 6 times with phenol free media. The UV-Vis-NIR spectra was collected using a BioTek plate reader. The results can be seen in
In embodiments, reliance on Triton may not be necessary.
The ICG J-aggregate loaded liposomes may be effectively utilized as a photoacoustic contrast agent. Photoacoustic (PA) imaging was performed to determine the PA response and stability of the ICG J-aggregate loaded liposomes. Each sample was exposed to seven different fluences to determine the stability of the nanoparticles over 900 laser pulses at each fluence. Each sample was first subjected to 900 pulses at 1 mJ/cm2. Then the same sample was subjected to 900 pulses at 2 mJ/cm2. This was repeated for 5, 10, 15, 20, and 25 mJ/cm2. Characteristic PA response curves can be seen in
The liposomes were imaged both in water and milk (whole, 3.25% fat) phantom to demonstrate feasibility in fatty environments. Samples were deposited in 3 mm diameter tubing and submerged in either water or milk. All images and spectra were acquired on a Vevo LAZR (VisulSonics, Toronto, Canada) system using a 21 MHz pre-clinical transducer with a 2.4 cm field of view, sub-millimeter spatial resolution, and a 5 Hz frame rate. For initial spectral characterization in water, images were acquired at wavelengths from 650-970 nm with a gain of 37 dB and persistence of 8. In milk, the gain was optimized to reduce background signal and set to 35 dB. Images were acquired at wavelengths of 650-970 nm with persistence of 8. As seen in
Cell phantoms were constructed to demonstrate the capabilities of the ICG J-aggregate loaded liposomes as contrast agents and sensors in a biological environment. Phantoms were constructed as follows. A 4% gelatin base was formed by dissolving 4 g of gelatin per 100 mL of water at 60° C. Macrophage cells (J774 A.1, 107/mL) were mixed with the ICG J-aggregate loaded liposomes, and with an absorbance of 10 OD at 890 nm for a 1 cm pathlength, in a 3:1 ratio. For some samples, a 100 μL cell/liposome solution was mixed with 5 μL of Triton X-100 to mimic activated macrophages and stimulate liposome disruption and incubated for 2 hours. An 8% gelatin solution was then mixed in a 1:1 ratio with the cell/liposome solution, and a 20 μL was placed on the set gelatin phantom base. Photoacoustic imaging was performed using Vevo 2100 and VevoLAZR, with a spectroscopic scan from 680-970 nm at a 1 mJ/cm2 laser fluence. Spectral curves were generated by selecting a small region inside of the inclusion and averaging the intensity for every wavelength.
Therefore, the present invention is well adapted to attain the ends and advantages mentioned as well as those that are inherent therein. The particular embodiments disclosed above are illustrative only, as the present invention may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Furthermore, no limitations are intended to the details of construction or design herein shown, other than as described in the claims below. It is therefore evident that the particular illustrative embodiments disclosed above may be altered or modified and all such variations are considered within the scope and spirit of the present invention. While compositions and methods are described in terms of “comprising,” “containing,” or “including” various components or steps, the compositions and methods can also “consist essentially of” or “consist of” the various components and steps. All numbers and ranges disclosed above may vary by some amount. Whenever a numerical range with a lower limit and an upper limit is disclosed, any number and any included range falling within the range is specifically disclosed. In particular, every range of values (of the form, “from about a to about b,” or, equivalently, “from approximately a to b,” or, equivalently, “from approximately a-b”) disclosed herein is to be understood to set forth every number and range encompassed within the broader range of values. Also, the terms in the claims have their plain, ordinary meaning unless otherwise explicitly and clearly defined by the patentee. Moreover, the indefinite articles “a” or “an,” as used in the claims, are defined herein to mean one or more than one of the element that it introduces. If there is any conflict in the usages of a word or term in this specification and one or more patent or other documents that may be incorporated herein by reference, the definitions that are consistent with this specification should be adopted.
This patent application is a national phase filing of the PCT patent application No. PCT/US2016/016916 filed 7 Feb. 2016, which in turn claims priority date benefit from a U.S. Provisional Patent Application No. 62/113,477 filed 8 Feb. 2015 with the same title and incorporated herewith in its entirety by reference.
This invention was made with government support under SBIR contract grant No. HHSN268201400039C entitled “Molecularly Targeted Liposomes for Detection of Macrophages in High Risk Artherosclerotic Plaque” and awarded by the National Heart, Lung and Blood Institute of The National Institutes of Health. The government has certain rights in the invention.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2016/016916 | 2/7/2016 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62113477 | Feb 2015 | US |
